国浩律师(上海)事务所 致:浙江医药股份有限公司 浙江医药股份有限公司(以下简称"公司")2024 年年度股东大会(以下 简称"本次股东大会")于 2025年 6 月 25 日在浙江省绍兴滨海新城致远中大道 168 号浙江医药总部2 号楼展厅召开。国浩律师(上海)事务所(以下简称"本 所"）接受公司委托,指派经办律师出席会议见证。 本所律师遵照《律师事务所从事证券法律业务管理办法》的有关执业要求, 根据《中华人民共和国证券法》《中华人民共和国公司法》(以下简称《公司法》) 以及中国证券监督管理委员会《上市公司股东会规则》等法律、法规及规范性文 件和《浙江医药股份有限公司章程》(以下简称《公司章程》)出具本法律意见 书。 本所律师系根据对事实的了解和对法律的理解,在对所有相关文件、资料和 信息进行核查判断的基础上,依法对本次股东大会有关事项发表法律意见。本所 律师同意公司将本法律意见书作为本次股东大会的必备文件公告。本所律师保证 本法律意见书不存在虎假、严重误导性陈述及重大遗漏,并愿意为此承担相应的 法律责任。 一、本次股东大会的召集、召开程序 (一) 本次股东大会的召集 公司董事会于 2025 年 5 月 3 ...

浙江医药股份有限公司 2024 年年度股东大会会议资料 2025 年 6 月 25 日 时 间：2025年6月25日 14:30 地 点：浙江省绍兴滨海新城致远中大道168号浙江医药总部2号楼展厅 主持人：董事长李男行先生 浙江医药股份有限公司 2024 年年度股东大会会议资料 | | | | 会议议程 1 | | | | | --- | --- | --- | --- | | 议案一《公司 | 2024 | 年度董事会工作报告》 | 2 | | 议案二《公司 | 2024 | 年度监事会工作报告》 | 8 | | 议案三《公司 | 2024 | 年度财务决算报告》 | 11 | | 议案四《公司 | 2024 | 年度利润分配预案》 | 16 | | 议案五《公司 | 2024 | 年年度报告》全文和摘要 | 17 | | 议案六《关于续聘会计师事务所并支付报酬的议案》 | | | 18 | | 议案七《关于购买董责险并授权公司经营层办理相关事宜的议案》 | | | 19 | | 议案八《关于取消监事会并修订<公司章程>的议案》 | | | 20 | | 议案九《关于新增、修订公司部分内部控制管理制度的议案 ...

一、FDA 现场检查的相关信息 7、检查结果：通过 二、生产车间及生产品种 证券代码：600216 证券简称：浙江医药 公告编号：2025-024 浙江医药股份有限公司 关于下属生产企业新昌制药厂通过美国 FDA 现场检查的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江医药股份有限公司（以下简称"公司"）下属生产企业新昌制药厂（以 下简称"新昌制药"）于 2025 年 03 月 04 日至 03 月 07 日接受了美国食品药品 监督管理局（以下简称"FDA"）的 CGMP（现行药品生产质量管理规范）现场检 查，检查范围涵盖了口服固体制剂和原料药的质量体系、物料、生产和实验室控 制四大系统。 近日，新昌制药收到 FDA 的通知函和针对本次检查签发的现场检查报告 （EIR），表明新昌制药符合美国药品 CGMP 质量体系要求，新昌制药顺利通过了 本次美国 FDA 的日常监督检查。根据法规 21CFR20.64(d)(3)，FDA 确认本次检查 已结束。现将相关信息公告如下： 由于未来的具体销售情况受市场环境等因素影 ...

证券代码：600216 证券简称：浙江医药 公告编号：2025-023 浙江医药股份有限公司 关于股份回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/4/15，由公司董事长李男行先生提议 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 4 月 4 14 日 | 年 | 15 | 日~2026 | 年 | 月 | | 预计回购金额 | 1亿元~2亿元 | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | | | □为维护公司价值及股东权益 | | | | | | | 累计已回购股数 | 4,494,800股 | | | | | | | 累计已回购股数占总股本比例 | 0.47% | | | | | | | 累计已回购金额 | 61,619,510元 | | | | | | | 实际回购 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600216 证券简称：浙江医药 公告编号：2025-021 浙江医药股份有限公司关于取消监事会并修订《公司章程》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 浙江医药股份有限公司（以下简称"公司"）于2025年5月30日以通讯表决方式召开了第十届六次董事会 会议，审议通过了《关于取消监事会并修订〈公司章程〉的议案》。根据《中华人民共和国公司法》 《上市公司章程指引》等相关规定，结合公司实际情况，公司不再设置监事会，监事会的职权由董事会 审计委员会行使，公司《监事会议事规则》等监事会相关制度相应废止，同时修订《公司章程》及公司 部分制度中涉及监事、监事会、股东会名称相关表述。《公司章程》主要修订情况如下： ■ 注：除上述修订外，还进行如下变更： ①按《公司法》要求，将涉及监事会职权的内容，由审计委员会承接； ②对原章程中的"股东大会"统一替换为"股东会"； ③"总裁"、"副总裁"、"财务总监"表述统一替换为"总经理"、"副总经理"、"财务负责人"；"总 ...

Group 1 - Huapei Power received a project intention letter from a domestic new energy vehicle company for a thermal management system PTC water heater, with an estimated sales amount of approximately 9 million yuan over a 5-year lifecycle starting from 2026 [1] - Antu Biotech obtained medical device registration certificates for products including "Cytomegalovirus IgM Antibody Test Kit" [1][2] - Yihong Technology adjusted the upper limit of its share repurchase price to 65.04 yuan per share, with a total repurchase amount of 6.9583 million yuan for 198,000 shares [2] Group 2 - Aihui Long received a medical device registration certificate for the Hepatitis B virus core antibody detection kit, valid until May 28, 2030 [2][3] - Quanxin Co. plans to engage in commodity futures hedging to mitigate raw material price fluctuations, with a maximum guarantee amount of 8 million yuan [3] - Jiahua Intelligent plans to lease idle assets in Dongguan for a total rental amount of approximately 6.3193 million yuan over 6 years [3] Group 3 - Qianjiang Biochemical announced the resignation of its chairman and a director, with a new chairman to be elected [4][5] - Aerospace Morning Light was suspended from participating in military procurement activities due to violations, with internal investigations underway [6] - Guang'an Aizhong intends to establish a fund with a total scale of 70.7 million yuan, focusing on distributed wind and solar power generation [7] Group 4 - Zhejiang Medicine plans to use up to 1 billion yuan of idle funds for entrusted wealth management, with a maximum investment period of 12 months [10] - Hengrui Medicine's subsidiary received approval for clinical trials of HRS9531 injection, aimed at treating type 2 diabetes patients [11] - Taiji Co. announced the purchase of 10 million yuan in wealth management products, with a minimum holding period of 6 months [12] Group 5 - Hong Kong-listed company Huichuang Pharmaceutical received approval for the clinical trial of a spray for treating primary premature ejaculation [26][27] - Haichuang Pharmaceutical's new drug application for a prostate cancer treatment was approved by the National Medical Products Administration [28] - Zhuhai Guanyu was selected as a designated supplier for low-voltage lithium batteries by SAIC Volkswagen [29] Group 6 - Huayi Technology opened a tax refund service for overseas travelers, enhancing its retail offerings [32] - Baobian Electric plans to transfer 90% of its subsidiary's shares for 137 million yuan [33] - Yiwei Communication intends to invest 100 million yuan to establish a wholly-owned subsidiary to enhance its strategic layout [34]

Group 1 - The Artemisinin concept sector rose by 1.17%, ranking 7th among concept sectors, with six stocks increasing in value, including Fosun Pharma, Zhejiang Medicine, and Haizheng Pharmaceutical, which rose by 5.23%, 4.94%, and 1.54% respectively [1] - The leading stocks in terms of net inflow of main funds were Zhejiang Medicine, Fosun Pharma, Baiyun Mountain, and Haizheng Pharmaceutical, with net inflows of 856.29 million, 545.22 million, 103.85 million, and 52.54 million respectively [1] - The main fund inflow rates for Zhejiang Medicine, Baiyun Mountain, and Fosun Pharma were 7.58%, 7.56%, and 3.62% respectively [2] Group 2 - The top gainers in the concept sector included pork, chicken farming, innovative drugs, and animal vaccines, while the top losers included controllable nuclear fusion and decelerators [1] - The overall market performance showed a mixed trend, with some sectors experiencing significant gains while others faced declines [1] - The trading volume and turnover rates varied among the stocks, indicating differing levels of investor interest and activity [2][3]

《上市公司股东会规则》 《上市公司治理准则》 《上海 证券交易所上市公司自律监管指引第 1 号——规范运作》和《浙江医药股份有限公司 章程》(以下简称《公司章程》)的规定，特制定本议事规则。 浙江医药股份有限公司 第十届六次董事会审议的内控制度汇编 目 录 股东会议事规则 第一章 总 则 第一条 为规范浙江医药股份有限公司(以下简称公司)行为，保证股东会依法行 使职权，根据《中华人民共和国公司法》(以下简称《公司法》)、《中华人民共和国 证券法》 （以下简称《证券法》）、 第二条 公司应严格按照法律、行政法规、《公司章程》及本规则的相关规定召 开股东会，保证股东能够依法行使权利。 公司董事会应切实履行职责，认真、按时组织股东会。公司全体董事应勤勉尽责， 确保股东会正常召开和依法行使职权。 第三条 股东会应当在《公司法》和《公司章程》规定的范围内行使职权。 第四条 本议事规则适用于公司年度股东会和临时股东会（以下统称"股东会"）。 年度股东会每年召开一次，应当于上一会计年度结束后的 6 个月内举行。临时股东会 不定期召开，出现《公司法》规定的应当召开临时股东会的情形时，临时股东会应当 在 2 个月内召开。 公司 ...

Core Viewpoint - Zhejiang Pharmaceutical Co., Ltd. has decided to abolish its supervisory board and amend its articles of association, transferring the supervisory powers to the audit committee of the board of directors [1][2]. Summary by Sections Company Structure Changes - The supervisory board will no longer be established, and its functions will be assumed by the audit committee of the board of directors [1]. - Relevant rules and regulations concerning the supervisory board will be abolished, and the articles of association will be revised accordingly [1]. Amendments to Articles of Association - The first article of the articles of association has been revised to include employees alongside shareholders and creditors in protecting legal rights [1]. - The role of the chairman as the legal representative of the company has been clarified, including the process for appointing a new legal representative within 30 days of resignation [2]. - New provisions state that the company will bear civil liability for damages caused by the legal representative while performing duties, with the right to seek compensation from the representative if at fault [3]. Shareholder Responsibilities and Rights - Shareholders are limited to their subscribed shares in terms of liability, and the company is responsible for its debts with all its assets [4]. - The articles clarify the definition of senior management personnel, including the general manager, financial director, and other specified roles [4]. - The issuance of shares will adhere to principles of openness, fairness, and justice, ensuring equal rights for all shares of the same category [5][6]. Capital Increase and Share Repurchase - The company can increase capital through various methods, including public issuance and private placements, subject to shareholder approval [21]. - The conditions for share repurchase have been updated, allowing for board resolutions under certain circumstances without needing a shareholder meeting [21]. Shareholder Meeting Procedures - The procedures for convening shareholder meetings have been updated, including the rights of shareholders to propose agenda items and the requirements for valid proposals [20][21]. - The articles now specify the responsibilities of the board and management in ensuring compliance with legal and regulatory requirements during shareholder meetings [22][24].

General Provisions - The company aims to protect the legal rights of shareholders, employees, and creditors while regulating its organization and behavior according to relevant laws [2] - The company is established as a joint-stock company in accordance with the Company Law and other regulations, formed by the merger of three entities [2] - The company was approved for public offering of shares in 1999 and is listed on the Shanghai Stock Exchange [3] Company Structure and Governance - The registered capital of the company is RMB 961,637,750 [3] - The company is a permanent joint-stock company, with the chairman acting as the legal representative [3] - Shareholders are liable for the company's debts only to the extent of their subscribed shares, while the company is liable for its debts with its entire assets [3][4] Business Objectives and Scope - The company's business objective is to develop new pharmaceutical products, enhance public health, and maintain competitive advantages in the pharmaceutical industry [4] - The company is engaged in various activities including drug production, hazardous chemicals management, food production, and technology consulting [4][5] Share Issuance and Management - The company issues shares in the form of stocks, adhering to principles of openness, fairness, and justice [6] - The total number of shares issued by the company is 961,637,750, with a structure primarily consisting of common shares [6] Shareholder Rights and Responsibilities - Shareholders have rights to dividends, attend meetings, supervise company operations, and request information [12] - Shareholders must comply with laws and the company's articles of association, and they cannot withdraw their capital except as legally permitted [17] Shareholder Meetings - The company holds annual and temporary shareholder meetings, with specific procedures for calling and conducting these meetings [47][49] - Decisions at shareholder meetings require a majority or two-thirds majority vote, depending on the nature of the resolution [79][81] Voting and Decision-Making - Shareholder voting is conducted through a named ballot, and the results are announced immediately [90] - Related shareholders are prohibited from voting on matters that involve conflicts of interest [37]